Uppsala, November 30, 2023. OssDsign AB (publ) today announced that SEB Venture Capital has sold its entire holding of about 7.44 million shares, corresponding to approximately 7.6 % of the shares in OssDsign.
“SEB Venture Capital has been a major shareholder in OssDsign during its development from a Swedish start-up as a cranial patient specific implant company to an international orthobiologics company with rapidly accelerating revenues. I am very pleased with the continued high interest from Swedish and international institutional investors to take part in the value creation we are expecting as OssDsign enters a new era”, commented Morten Henneveld, CEO of OssDsign.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: email@example.com
The Company’s Certified Adviser is Carnegie Investment Bank AB (publ)
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.